UNITED STATES

                     SECURITIES AND EXCHANGE COMMISSION

                           Washington, D.C. 20549

                                  FORM 10-Q


              Quarterly Report Pursuant to Section 13 or 15(d)
                   of the Securities Exchange Act of 1934


             For the quarterly period ended  February 28, 1998
                                            -------------------

                       Commission file number 1-11479
                                              -------

                                E-Z-EM, Inc.
           ------------------------------------------------------
           (Exact name of registrant as specified in its charter)


                   Delaware                          11-1999504
        -------------------------------          -------------------
        (State or other jurisdiction of           (I.R.S. Employer
        incorporation or organization)           Identification No.)


             717 Main Street, Westbury, New York            11590
          ----------------------------------------       ----------
          (Address of principal executive offices)       (Zip Code)


                               (516) 333-8230
             --------------------------------------------------
             Registrant's telephone number, including area code




Indicate by check mark whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act
of 1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to
such filing requirements for the past 90 days.

                          Yes    X      No
                              -------      -------

On April 10, 1998, there were 4,035,346 shares of the registrant's Class A
Common Stock outstanding and 5,969,335 shares of the registrant's Class B
Common Stock outstanding.






                                Page 1 of 22
                          Exhibit Index on Page 19
<PAGE>

                        E-Z-EM, Inc. and Subsidiaries

                                    INDEX
                                    -----

Part I:  Financial Information                                    Page
------   ---------------------                                    ----

  Item 1.  Financial Statements


    Consolidated Balance Sheets - February 28, 1998
      May 31, 1997                                                3 - 4


    Consolidated Statements of Operations - thirteen
      and thirty-nine weeks ended February 28, 1998 and
      March 1, 1997                                                 5


    Consolidated Statement of Stockholders' Equity -
      thirty-nine weeks ended February 28, 1998                     6


    Consolidated Statements of Cash Flows - thirty-nine
      weeks ended February 28, 1998 and March 1, 1997             7 - 8


    Notes to Consolidated Financial Statements                    9 - 11


  Item 2.  Management's Discussion and Analysis of Financial
             Condition and Results of Operations                 12 - 18


Part II:  Other Information
-------   -----------------

  Item 6.  Exhibits and Reports on Form 8-K                        19




















                                     -2-
<PAGE>

                        E-Z-EM, Inc. and Subsidiaries

                         CONSOLIDATED BALANCE SHEETS
                               (in thousands)


                                                 February 28,     May 31,
               ASSETS                                1998          1997
                                                    ------        ------
                                                 (unaudited)     (audited)

CURRENT ASSETS
  Cash and cash equivalents                        $ 4,886      $  4,484
  Debt and equity securities                         3,423        10,991
  Accounts receivable, principally
    trade, net                                      18,221        16,971
  Inventories                                       27,759        27,351
  Other current assets                               3,379         4,147
                                                    ------       -------
      Total current assets                          57,668        63,944

INVESTMENT IN AFFILIATE                              1,190

PROPERTY, PLANT AND EQUIPMENT - AT COST,
  less accumulated depreciation and
  amortization                                      22,171        23,418

COST IN EXCESS OF FAIR VALUE OF NET ASSETS
  ACQUIRED, less accumulated amortization              460           489

INTANGIBLE ASSETS, less accumulated
  amortization                                       2,603         7,057

DEBT AND EQUITY SECURITIES                           2,011         2,081

OTHER ASSETS                                         3,632         3,731
                                                    ------       -------
                                                   $89,735      $100,720
                                                    ======       =======



















The accompanying notes are an integral part of these financial statements.

                                     -3-
<PAGE>

                        E-Z-EM, Inc. and Subsidiaries

                         CONSOLIDATED BALANCE SHEETS
               (in thousands, except share and per share data)


                                                 February 28,     May 31,
     LIABILITIES AND STOCKHOLDERS' EQUITY            1998          1997
                                                    ------        ------
                                                 (unaudited)     (audited)

CURRENT LIABILITIES
  Notes payable                                    $ 2,913      $  7,029
  Current maturities of long-term debt                 298           517
  Accounts payable                                   6,698         6,168
  Accrued liabilities                                6,837         6,829
  Accrued income taxes                                 370           286
                                                    ------       -------
      Total current liabilities                     17,116        20,829

LONG-TERM DEBT, less current maturities              1,003           842

OTHER NONCURRENT LIABILITIES                         1,728         1,805

COMMITMENTS AND CONTINGENCIES
                                                    ------       -------
      Total liabilities                             19,847        23,476
                                                    ------       -------
STOCKHOLDERS' EQUITY
  Preferred stock, par value $.10 per
    share - authorized, 1,000,000 shares;
    issued, none                                        -             -
  Common stock
    Class A (voting), par value $.10 per
      share - authorized, 6,000,000 shares;
      issued and outstanding 4,035,346 shares
      at February 28, 1998 and May 31, 1997            403           403
    Class B (nonvoting), par value $.10 per
      share - authorized, 10,000,000 shares;
      issued and outstanding 5,932,952 shares
      at February 28, 1998 and 5,600,883
      shares at May 31, 1997                           593           560
  Additional paid-in capital                        21,300        19,073
  Retained earnings                                 47,991        57,087
  Unrealized holding gain on debt and equity
    securities                                       1,303         1,332
  Cumulative translation adjustments                (1,702)       (1,211)
                                                    ------       -------
      Total stockholders' equity                    69,888        77,244
                                                    ------       -------
                                                   $89,735      $100,720
                                                    ======       =======






The accompanying notes are an integral part of these financial statements.

                                     -4-
<PAGE>

                         E-Z-EM, Inc. and Subsidiaries

                     CONSOLIDATED STATEMENTS OF OPERATIONS
                                  (unaudited)


                             Thirteen weeks ended     Thirty-nine weeks ended
                            -----------------------   -----------------------
                            February 28,   March 1,   February 28,   March 1,
                                1998         1997         1998         1997
                               ------       ------       ------       ------
                              (in thousands, except share and per share data)

Net sales                     $24,385      $23,576      $74,809      $72,923

Cost of goods sold             16,146       14,954       48,114       44,185
                               ------       ------       ------       ------
      Gross profit              8,239        8,622       26,695       28,738
                               ------       ------       ------       ------
Operating expenses
  Selling and administrative    8,379        8,325       24,923       24,832
  Research and development      1,410        1,792        4,491        4,767
  Impairment of long-lived
    assets                      4,121                     4,121
                               ------       ------       ------       ------
    Total operating expenses   13,910       10,117       33,535       29,599
                               ------       ------       ------       ------
      Operating loss           (5,671)      (1,495)      (6,840)        (861)

Other income (expense)
  Interest income                 248          181          577          603
  Interest expense               (206)        (149)        (572)        (290)
  Other, net                     (249)          40         (385)         140
                                -----        -----        -----        -----
      Loss before income
        taxes                  (5,878)      (1,423)      (7,220)        (408)

Income tax benefit                (59)        (377)        (154)        (118)
                                -----        -----        -----        -----
      NET LOSS                $(5,819)     $(1,046)     $(7,066)     $  (290)
                                =====        =====        =====        =====

Loss per common share
  Basic and diluted           $  (.58)     $  (.11)     $  (.71)     $  (.03)
                                =====        =====        =====        =====

Weighted average common shares
  Basic and diluted         9,949,328    9,891,783    9,933,922    9,854,233
                            =========    =========    =========    =========










The accompanying notes are an integral part of these financial statements.

                                     -5-
<PAGE>

                        E-Z-EM, Inc. and Subsidiaries

               CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY

                 Thirty-nine weeks ended February, 28, 1998
                                 (unaudited)
                      (in thousands, except share data)

<TABLE>
<CAPTION>
                                                                                             Unrealized
                                      Class A            Class B                            holding gain
                                    common stock       common stock    Additional             on debt    Cumulative
                                 -----------------  -----------------   paid-in    Retained  and equity  translation
                                   Shares   Amount    Shares   Amount   capital    earnings  securities  adjustments   Total
                                 ---------  ------  ---------  ------  ----------  --------  ----------  -----------  -------
<S>                              <C>         <C>    <C>         <C>     <C>        <C>         <C>         <C>        <C>
Balance at May 31, 1997          4,035,346   $403   5,600,883   $560    $19,073    $57,087     $1,332      $(1,211)   $77,244

Exercise of stock options                              41,396      4        178                                           182
Income tax benefits on
  stock options exercised                                                    40                                            40
Compensation related to
  stock option plans                                                          5                                             5
Issuance of stock                                         925                 5                                             5
3% common stock dividend                              289,748     29      1,999     (2,030)                                (2)
Net loss                                                                            (7,066)                            (7,066)
Unrealized holding loss on debt
  and equity securities                                                                           (29)                    (29)
Foreign currency translation
  adjustments                    _________    ___   _________    ___     ______     ______      _____        _(491)    __(491)

Balance at February 28, 1998     4,035,346   $403   5,932,952   $593    $21,300    $47,991     $1,303      $(1,702)   $69,888
                                 =========    ===   =========    ===     ======     ======      =====        =====     ======
</TABLE>
























The accompanying notes are an integral part of this financial statement.

                                     -6-
<PAGE>

                        E-Z-EM, Inc. and Subsidiaries

                    CONSOLIDATED STATEMENTS OF CASH FLOWS
                                 (unaudited)


                                                 Thirty-nine weeks ended
                                                 ------------------------
                                                 February 28,    March 1,
                                                     1998          1997
                                                    ------        ------
                                                       (in thousands)

Cash flows from operating activities:
  Net loss                                         $(7,066)      $  (290)
  Adjustments to reconcile net loss to
    net cash used in operating activities
      Depreciation and amortization                  2,533         2,216
      Impairment of long-lived assets                4,121
      Provision for doubtful accounts                  202           122
      Equity in losses of affiliate                    150
      Loss on sale of investments                                     18
      Deferred income tax provision                     14           219
      Other non-cash items                               5
      Changes in operating assets and
        liabilities
          Accounts receivable                       (1,452)       (2,366)
          Inventories                                 (408)       (3,901)
          Other current assets                         685        (1,131)
          Other assets                                 126          (492)
          Accounts payable                             530           873
          Accrued liabilities                            6          (335)
          Accrued income taxes                          70           (60)
          Other noncurrent liabilities                 (53)           (2)
                                                    ------        ------
            Net cash used in operating
              activities                              (537)       (5,129)
                                                    ------        ------
Cash flows from investing activities:
  Additions to property, plant and
    equipment, net                                    (858)       (3,965)
  Acquisition of business                                         (7,096)
  Investment in affiliate                           (1,340)
  Available-for-sale securities
    Purchases                                       (8,840)      (16,880)
    Proceeds from sale                              16,408        26,214
                                                    ------        ------
      Net cash provided by (used in)
        investing activities                         5,370        (1,727)
                                                    ------        ------
Cash flows from financing activities:
  Proceeds from issuance of debt                     3,436         6,432
  Repayments of debt                                (7,380)         (699)
  Proceeds from exercise of stock options,
    including related income tax benefits              222           707
  Proceeds from issuance of stock in
    connection with the stock purchase plan              5             9
                                                    ------        ------
      Net cash (used in) provided by
        financing activities                        (3,717)        6,449
                                                    ------        ------

                                     -7-
<PAGE>

                        E-Z-EM, Inc. and Subsidiaries

              CONSOLIDATED STATEMENTS OF CASH FLOWS (continued)
                                 (unaudited)


                                                 Thirty-nine weeks ended
                                                 ------------------------
                                                 February 28,    March 1,
                                                     1998          1997
                                                    ------        ------
                                                       (in thousands)

Effect of exchange rate changes on
  cash and cash equivalents                         $ (714)       $ (122)
                                                     -----         -----
      INCREASE (DECREASE) IN CASH AND
        CASH EQUIVALENTS                               402          (529)

Cash and cash equivalents
  Beginning of period                                4,484         3,363
                                                     -----         -----
  End of period                                     $4,886        $2,834
                                                     =====         =====

Supplemental disclosures of cash
  flow information:
    Cash paid (refunded) during the period for:
      Interest                                      $  580        $  232
                                                     =====         =====
      Income taxes (net of refunds of $1,314 and
        $421 in 1998 and 1997, respectively)       $(1,031)       $  228
                                                     =====         =====


























The accompanying notes are an integral part of these financial statements.

                                     -8-
<PAGE>

                        E-Z-EM, Inc. and Subsidiaries

                 NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

                     February 28, 1998 and March 1, 1997
                                 (unaudited)


NOTE A - CONSOLIDATED FINANCIAL STATEMENTS

  The consolidated balance sheet as of February 28, 1998, the consolidated
    statement of stockholders' equity for the period ended February 28,
    1998, and the consolidated statements of operations and cash flows for
    the periods ended February 28, 1998 and March 1, 1997, have been
    prepared by the Company without audit.  In the opinion of management,
    all adjustments (which include only normally recurring adjustments)
    necessary to present fairly the financial position, changes in
    stockholders' equity, results of operations and cash flows at February
    28, 1998 (and for all periods presented) have been made.

  Certain information and footnote disclosures, normally included in
    financial statements prepared in accordance with generally accepted
    accounting principles, have been condensed or omitted.  It is suggested
    that these consolidated financial statements be read in conjunction with
    the financial statements and notes thereto included in the fiscal 1997
    Annual Report on Form 10-K filed by the Company on August 29, 1997.  The
    results of operations for the periods ended February 28, 1998 and March
    1, 1997 are not necessarily indicative of the operating results for the
    respective full years.

  The consolidated financial statements include the accounts of E-Z-EM, Inc.
    and all 100%-owned subsidiaries (the "Company").  The Company's
    approximately 23% interest in an affiliate is accounted for by the
    equity method.  Pursuant to this method, such investment is recorded at
    cost and adjusted by the Company's share of undistributed earnings (or
    losses).


NOTE B - EARNINGS (LOSS) PER COMMON SHARE

  Effective December 31, 1997, the Company adopted Statement of Financial
    Accounting Standards No. 128 ("SFAS 128"), "Earnings Per Share," which
    requires dual presentation of basic and diluted earnings per share
    ("EPS") on the face of the statement of operations for all periods
    presented.  Basic EPS excludes dilution and is computed by dividing
    income (loss) available to common shareholders by the weighted average
    number of common shares outstanding during the period.  Diluted EPS
    reflects the potential dilution that could occur if securities or other
    contracts to issue common stock were exercised or converted into common
    stock or resulted in the issuance of common stock that then shared in
    the earnings of the entity.  Diluted EPS is computed similarly to fully
    diluted EPS pursuant to Accounting Principles Board Opinion No. 15.
    Common stock equivalents were excluded from the diluted calculation for
    the periods ended February 28, 1998 and March 1, 1997, as their effects
    were anti-dilutive.  Prior period amounts have been restated, where
    appropriate, to conform to the requirements of SFAS 128.



                                     -9-
<PAGE>

                        E-Z-EM, Inc. and Subsidiaries

                 NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

                     February 28, 1998 and March 1, 1997
                                 (unaudited)


NOTE C - INVENTORIES

  Inventories consist of the following:

                                                 February 28,     May 31,
                                                     1998          1997
                                                    ------        ------
                                                       (in thousands)

    Finished goods                                 $13,703       $14,170
    Work in process                                  1,876         1,639
    Raw materials                                   12,180        11,542
                                                    ------        ------
                                                   $27,759       $27,351
                                                    ======        ======


NOTE D - INVESTMENT IN EQUITY AFFILIATE

  In August 1997, the Company acquired approximately 23% of ITI Medical
    Technologies, Inc. ("ITI") for $1,340,000, including acquisition related
    expenses of $40,000.  ITI is a California corporation, based in
    Livermore, California, which develops and manufactures MRI diagnostic
    and therapeutic medical devices.  The Company's investment in ITI is
    accounted for by the equity method.  Pursuant to this method, such
    investment is recorded at cost and adjusted by the Company's share of
    undistributed earnings (or losses).


NOTE E - IMPAIRMENT OF LONG-LIVED ASSETS

  In accordance with Statement of Financial Accounting Standards No. 121,
    "Accounting for the Impairment of Long-Lived Assets and for Long-Lived
    Assets to be Disposed Of," the Company recorded an impairment charge
    with no associated tax benefit of $4,121,000, or $.41 per share,
    relating to certain long-lived assets used in the cardiovascular market.
    The revenue potential of this cardiovascular technology was impaired due
    to price erosion for stents and angioplasty products, increasing product
    competition and the Company's strategic decision to focus its efforts in
    the interventional radiology market.  The Company has determined that it
    needs to find a strategic business partner with an existing
    cardiovascular sales and marketing franchise in order to be successful
    in the cardiovascular market, although there are no assurances that such
    a partner can be found.  The charge represents the difference between
    the carrying value of intangible assets and the fair market value of
    these assets based on estimated future cash flows discounted at a rate
    commensurate with the risk involved.  The charge had no impact on the
    Company's cash flow or its ability to generate cash flow in the future.
    As a result of the impairment charge, amortization expense related to
    these assets will decrease by approximately $250,000 per year.


                                    -10-
<PAGE>

                        E-Z-EM, Inc. and Subsidiaries

                 NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

                     February 28, 1998 and March 1, 1997
                                 (unaudited)


NOTE F - COMMON STOCK

  Under the 1983 and 1984 Stock Option Plans, options for 41,396 shares were
    exercised at prices ranging from $4.22 to $5.55 per share, options for
    4,230 shares were forfeited at prices ranging from $5.55 to $8.84 per
    share, options for 869 shares expired at $8.74 per share, and no options
    were granted during the thirty-nine weeks ended February 28, 1998.
    Under the 1997 AngioDynamics Stock Option Plan, options for 6.53 shares
    were granted at $80,000 per share, options for .74 shares were forfeited
    at $80,000 per share, and no options were exercised or expired during
    the thirty-nine weeks ended February 28, 1998.

  Under the Employee Stock Purchase Plan, 925 shares were purchased at
    $6.01 per share during the thirty-nine weeks ended February 28, 1998.
    Total proceeds received by the Company approximated $5,000.

  On January 23, 1998, the Board of Directors declared a 3% stock dividend
    on shares of Class A and Class B Common Stock.  The dividend, payable in
    nonvoting Class B Stock, was distributed on March 16, 1998 to
    shareholders of record on February 26, 1998.


NOTE G - CONTINGENCIES

  During August and December 1997, the Company settled two product liability
    actions in which it had been a defendant.  Such actions were settled for
    amounts under the Company's insurance limit and the amounts contributed
    by the Company were not material to its consolidated financial
    statements.

  The Company has been sued by Olympia Holding Corporation p/k/a P-I-E
    Nationwide, Inc. for $443,830.  The suit, filed on October 5, 1992, is
    presently pending in the U.S. Bankruptcy Court for the Middle District
    of Florida.  The Company is being represented in this action by a law
    firm which is also representing numerous other defendants being sued by
    the same plaintiff on the same grounds - recovery for alleged
    undercharges for freight carriage.  It is not possible, at this stage,
    to determine what, if any, liability exists with respect to the Company
    in this matter.  The Company will continue to vigorously defend against
    this action; it has been informed by legal counsel that there exist
    numerous valid defenses to this case.


NOTE H - RECLASSIFICATIONS

  Certain reclassifications have been made to the prior period amounts to
    conform to the current period presentations.




                                    -11-
<PAGE>

                        E-Z-EM, Inc. and Subsidiaries

                    MANAGEMENT'S DISCUSSION AND ANALYSIS
              OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS


Quarters ended February 28, 1998 and March 1, 1997
--------------------------------------------------

     The Company's quarters ended February 28, 1998 and March 1, 1997 both
represent thirteen weeks.

Results of Operations
---------------------

     Segment Overview
     ----------------

     The Company operates in two industry segments:  Diagnostic products and
AngioDynamics products.  The Diagnostic products industry segment includes
both contrast systems and non-contrast systems.

                              Diagnostic  AngioDynamics  Eliminations  Total
                              ----------  -------------  ------------  -----
                                              (in thousands)

Quarter ended February 28, 1998
-------------------------------

  Unaffiliated customer sales  $19,878        $4,507           -      $24,385
  Intersegment sales                              82         ($82)        -
  Gross profit (loss)            6,488         1,761          (10)      8,239
  Operating loss                  (406)       (5,255)         (10)     (5,671)

Quarter ended March 1, 1997
---------------------------

  Unaffiliated customer sales  $18,916        $4,660           -      $23,576
  Intersegment sales               303           346        ($649)        -
  Gross profit                   6,343         2,273            6       8,622
  Operating profit (loss)       (1,229)         (272)           6      (1,495)

     Diagnostic Products
     -------------------

     Diagnostic segment operating results for the current quarter improved
by $823,000 due to a 3% sales increase, as well as reduced operating
expenses of $678,000.  Previous price increases virtually offset the effect
of increased discounts to group purchasing organizations.  Gross profit
expressed as a percentage of net sales was 33% during both the current
quarter and comparable quarter of the prior year, as the effects of
increased discounts to group purchasing organizations, were offset by
reduced unabsorbed overhead costs associated with the manufacturing site
relocation.

     AngioDynamics Products
     ----------------------

     AngioDynamics segment operating results for the current quarter, which
declined by $4,983,000, were adversely affected by a non-cash accounting
charge with no associated tax benefit of $4,121,000, or $.41 per share,
relating to an impairment of certain long-lived assets used in the
cardiovascular market.  The fact that the Company did not record a tax
benefit for financial reporting purposes, associated with the impairment
charge, does not affect its ability to realize the deduction for tax
purposes.  The revenue potential of this cardiovascular technology was

                                    -12-
<PAGE>

impaired due to price erosion for stents and angioplasty products,
increasing product competition and the Company's strategic decision to focus
its efforts in the interventional radiology market.  The Company has
determined that it needs to find a strategic business partner with an
existing cardiovascular sales and marketing franchise in order to be
successful in the cardiovascular market, although there are no assurances
that such a partner can be found.  The charge had no impact on the Company's
cash flow or its ability to generate cash flow in the future.  As a result
of the impairment charge, amortization expense related to these assets will
decrease by approximately $250,000 per year.

     Operating results were also impacted by an overall sales decline, lower
gross profit and an increase in operating expenses before impairment
charges.  Domestic sales improved by $680,000, or 23%, due to continued
market penetration, while international sales decreased $833,000, or 51%,
due to a decline in sales of the AngioStent.  Overall, AngioDynamics sales
decreased 3% during the current quarter.  Gross profit expressed as a
percentage of net sales declined to 38% during the current quarter versus
45% during the comparable quarter of the prior year due primarily to lower
stent sales, price erosion in the coronary stent marketplace, and
underutilized capacity at the Irish manufacturing facility.  Operating
expenses before impairment charges increased $349,000 due, in part, to
termination costs of $78,000 associated with the relocation of the Leocor
operations during the current quarter.

     Consolidated Results of Operations
     ----------------------------------

     For the quarter ended February 28, 1998, the Company reported a net
loss of $5,819,000 or ($.58) per common share on both a basic and diluted
basis, as compared to a net loss of $1,046,000 or ($.11) per common share on
both a basic and diluted basis, for the comparable period of last year.

     Results for the current quarter were adversely affected by the
AngioDynamics impairment charge of $4,121,000, or $.41 per share.  Reduced
Diagnostic operating expenses of $678,000 offset lower AngioDynamics gross
profit.  The lower AngioDynamics gross profit is due to lower stent sales,
price erosion in the coronary stent marketplace, and underutilized capacity
at the Irish manufacturing facility.

     Net sales for the quarter ended February 28, 1998 increased 3%, or
$809,000, as compared to the quarter ended March 1, 1997 due primarily to
increased sales of non-contrast systems of $1,747,000, partially offset by
decreased sales of contrast systems of $785,000 and AngioDynamics products
of $153,000.  Previous price increases, net of discounts to group purchasing
organizations, had little effect on net sales in the current quarter.  Net
sales in international markets, including direct exports from the U.S.,
decreased 3%, or $237,000, in the current quarter versus the comparable
period of last year due to decreased sales of AngioDynamics products of
$833,000 and contrast systems of $347,000, partially offset by increased
sales of non-contrast systems of $943,000.

     Gross profit expressed as a percentage of net sales decreased to 34%
during the current quarter from 37% in the comparable quarter of the prior
year due primarily to reduced AngioDynamics gross profit, resulting from
lower stent sales, price erosion in the coronary stent marketplace, and
underutilized capacity at the Irish manufacturing facility.  In the
Diagnostic segment, the effects of increased discounts to group purchasing
organizations, were offset by reduced unabsorbed overhead costs associated

                                    -13-
<PAGE>

with the manufacturing site relocation.  The Company's third fiscal quarters
traditionally have fewer production days than the other fiscal quarters,
resulting in somewhat lower gross profit percentages in such quarters.

     Selling and administrative ("S&A") expenses were $8,379,000 during the
quarter ended February 28, 1998 versus $8,325,000 during the quarter ended
March 1, 1997.  There were no materially significant factors affecting the
quarterly comparison of S&A expenses.

     Research and development ("R&D") expenditures decreased 21% in the
current quarter to $1,410,000, or 6% of net sales, from $1,792,000, or 8% of
net sales, in the comparable quarter of the prior year due to decreased
regulatory expenses.  Of the R&D expenditures in the current quarter,
approximately 42% relate to contrast systems, 38% to AngioDynamics projects,
9% to general regulatory costs, 3% to immunological projects, and 8% to
other projects.  R&D expenditures are expected to continue at approximately
current levels.

     Other income, net of expenses, decreased $279,000 in the current
quarter versus the comparable period of last year due primarily to the
recording of a life insurance gain of $169,000 in the prior year, increased
foreign currency exchange losses of $97,000, and the recording of the
Company's approximate 23% share in the losses of ITI Medical Technologies,
Inc. ("ITI") of $70,000.

     For the quarter ended February 28, 1998, the Company's unusually low
effective tax benefit rate of 1% differed from the Federal statutory tax
rate of 34% due primarily to the fact that the Company did not provide for
the tax benefit on losses (including the impairment charge) incurred in
certain jurisdictions, since, it is more likely than not that such benefits
will not be realized.  Losses incurred in a foreign jurisdiction subject to
lower tax rates also contributed to the unusually low effective tax benefit
rate.  For the quarter ended March 1, 1997, the Company's effective tax
benefit rate of 26% differed from the Federal statutory tax rate of 34% due
primarily to the fact that the Company did not provide for the tax benefit
on losses incurred in a foreign jurisdiction, since, at that time, it was
more likely than not that such benefits would not be realized, and losses
incurred in a foreign jurisdiction subject to lower tax rates, partially
offset by earnings of the Company's Puerto Rican subsidiary, which are
subject to favorable U.S. tax treatment.

















                                    -14-
<PAGE>

Thirty-nine weeks ended February 28, 1998 and March 1, 1997
-----------------------------------------------------------

Results of Operations
---------------------

     Segment Overview
     ----------------

                              Diagnostic  AngioDynamics  Eliminations  Total
                              ----------  -------------  ------------  -----
                                              (in thousands)

Thirty-nine weeks ended February 28, 1998
-----------------------------------------

  Unaffiliated customer sales  $61,080       $13,729           -      $74,809
  Intersegment sales                59           363        ($422)        -
  Gross profit (loss)           21,918         4,801          (24)     26,695
  Operating profit (loss)          669        (7,485)         (24)     (6,840)

Thirty-nine weeks ended March 1, 1997
-------------------------------------

  Unaffiliated customer sales  $58,775       $14,148           -      $72,923
  Intersegment sales               685           775      ($1,460)        -
  Gross profit (loss)           21,494         7,269          (25)     28,738
  Operating loss                  (770)          (66)         (25)       (861)

     Diagnostic Products
     -------------------

     Diagnostic segment operating results for the current period improved by
$1,439,000 due to a 3% sales increase, as well as reduced operating expenses
of $1,016,000.  Previous price increases virtually offset the effect of
increased discounts to group purchasing organizations.  Gross profit
expressed as a percentage of net sales was 36% during both the current
period and comparable period of the prior year, as the effects of increased
discounts to group purchasing organizations, were offset by reduced
unabsorbed overhead costs associated with the manufacturing site relocation.

     AngioDynamics Products
     ----------------------

     AngioDynamics segment operating results for the current period, which
declined by $7,419,000, were adversely affected by a non-cash accounting
charge with no associated tax benefit of $4,121,000, or $.41 per share,
relating to an impairment of certain long-lived assets used in the
cardiovascular market.  The fact that the Company did not record a tax
benefit for financial reporting purposes, associated with the impairment
charge, does not affect its ability to realize the deduction for tax
purposes.

     Operating results were also impacted by an overall sales decline, lower
gross profit and an increase in operating expenses before impairment
charges.  Domestic sales improved by $2,287,000, or 27%, due to continued
market penetration, while international sales decreased $2,705,000, or 47%,
due to a decline in sales of the AngioStent.  Overall, AngioDynamics sales
decreased 3% during the current period.  Gross profit expressed as a
percentage of net sales declined to 34% during the current period versus 49%
during the comparable period of the prior year due primarily to lower stent
sales, price erosion in the coronary stent marketplace, underutilized
capacity at the Irish manufacturing facility, and increased inventory
reserves of $627,000.  Operating expenses before impairment charges
increased $830,000 due, in part, to the Leocor operations, which began in
the third quarter of last fiscal year, and termination costs of $179,000

                                    -15-
<PAGE>

associated with the relocation of the Leocor operations during the current
fiscal year.

     Consolidated Results of Operations
     ----------------------------------

     For the thirty-nine weeks ended February 28, 1998, the Company reported
a net loss of $7,066,000 or ($.71) per common share on both a basic and
diluted basis, as compared to a net loss of $290,000 or ($.03) per common
share on a basic and diluted basis for the comparable period of last year.

     Results for the current period were adversely impacted by the
AngioDynamics impairment charge of $4,121,000, or $.41 per share, as well as
lower AngioDynamics gross profit, resulting from lower stent sales, price
erosion in the coronary stent marketplace, underutilized capacity at the
Irish manufacturing facility, and increased inventory reserves of $627,000.

     Net sales for the thirty-nine weeks ended February 28, 1998 increased
3%, or $1,886,000, as compared to the thirty-nine weeks ended March 1, 1997
due primarily to increased sales of non-contrast systems of $3,348,000,
partially offset by decreased sales of contrast systems of 1,043,000 and
AngioDynamics products of $419,000.  Previous price increases, net of
discounts to group purchasing organizations, had little effect on net sales
in the current period.  Net sales in international markets, including direct
exports from the U.S., decreased 8%, or $2,190,000, in the current period
versus the comparable period of last year due to decreased sales of
AngioDynamics products of $2,705,000 and contrast systems of $995,000,
partially offset by increased sales of non-contrast systems of $1,510,000.

     Gross profit expressed as a percentage of net sales decreased to 36%
during the current period from 39% in the comparable period of last year due
primarily to reduced AngioDynamics gross profit, resulting from lower stent
sales, price erosion in the coronary stent marketplace, underutilized
capacity at the Irish manufacturing facility, and increased inventory
reserves of $627,000.  In the Diagnostic segment, the effects of increased
discounts to group purchasing organizations, were offset by reduced
unabsorbed overhead costs associated with the manufacturing site relocation.

     S&A expenses were $24,923,000 during the thirty-nine weeks ended
February 28, 1998 versus $24,832,000 during the thirty-nine weeks ended
March 1, 1997.  This increase of $91,000, or less than 1%, in the current
period was due to increased AngioDynamics S&A expenses of $1,079,000, offset
by decreased Diagnostic S&A expenses of $988,000.  Increased AngioDynamics
S&A expenses can be attributed, in part, to the Leocor operations, which
began in the third quarter of last fiscal year, and termination costs of
$179,000 associated with the relocation of the Leocor operations during the
current fiscal year.

     R&D expenditures decreased 6% in the current period to $4,491,000, or
6% of net sales, from $4,767,000, or 7% of net sales, in the comparable
prior year period.  This decrease was due primarily to decreases in
regulatory expenses of $420,000 and AngioDynamics project spending of
$248,000, partially offset by increased contrast system spending of
$377,000.  Of the R&D expenditures in the current period, approximately 42%
relate to contrast systems, 32% to AngioDynamics projects, 10% to general
regulatory costs, 3% to immunological projects, and 13% to other projects.

     Other income, net of expenses, decreased $833,000 in the current period
versus the comparable period of last year due primarily to increased

                                    -16-
<PAGE>

interest expense of $282,000, resulting from AngioDynamics bank financing,
increased foreign currency exchange losses of $282,000, and the recording of
the Company's approximate 23% share in the losses of ITI of $150,000.

     For the thirty-nine weeks ended February 28, 1998, the Company's
unusually low effective tax benefit rate of 2% differed from the Federal
statutory tax rate of 34% due primarily to the fact that the Company did not
provide for the tax benefit on losses (including the impairment charge)
incurred in certain jurisdictions, since, it is more likely than not that
such benefits will not be realized.  Losses incurred in a foreign
jurisdiction subject to lower tax rates also contributed to the unusually
low effective tax benefit rate.  The Company's effective tax benefit rate of
29% during the thirty-nine weeks ended March 1, 1997 differed from the
Federal statutory tax rate of 34% due primarily to non-deductible expenses,
losses incurred in a foreign jurisdiction subject to lower tax rates, and
the fact that the Company did not provide for the tax benefit on losses
incurred in a foreign jurisdiction, since, at that time, it was more likely
than not that such benefits would not be realized, partially offset by
earnings of the Company's Puerto Rican subsidiary, which are subject to
favorable U.S. tax treatment, and tax-exempt interest income.

Liquidity and Capital Resources
-------------------------------

     During the thirty-nine weeks ended February 28, 1998, debt repayments,
investment in affiliate and capital expenditures were funded primarily by
cash reserves.  In the past, the Company's policy had been to fund capital
requirements without incurring significant debt.  At February 28, 1998, debt
(notes payable, current maturities of long-term debt and long-term debt) was
$4,214,000 as compared to $8,388,000 at May 31, 1997.  The Company has
available $8,921,000 under four bank lines of credit of which $1,723,000 was
outstanding at February 28, 1998.

     The Company's current policy is to issue stock dividends.  During the
third quarter of fiscal years 1996 and 1998 and the fourth quarter of fiscal
year 1997, the Company issued 3% stock dividends.

     Presently, the Company is continuing to look for both new and
complementary lines of business for expansion in order to ensure its
continued growth.

     At February 28, 1998, approximately 60% of the Company's assets consist
of inventories, accounts receivable, cash and cash equivalents, and debt and
equity securities.  Prior to fiscal 1998, inventories have increased at a
greater rate than sales as a result of broadened product lines, and safety
stock during the relocation of a portion of the Company's contrast systems
manufacturing operations.  The current ratio is 3.37 to 1, with net working
capital of $40,552,000 at February 28, 1998, as compared to the current
ratio of 3.07 to 1, with net working capital of $43,115,000 at May 31, 1997.

     This Form 10-Q contains certain forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended (the
"Securities Act"), and Section 21E of the Securities Exchange Act of 1934,
as amended (the "Exchange Act"), which are intended to be covered by the
safe harbors created thereby.  Investors are cautioned that all forward-
looking statements involve risks and uncertainty, including without
limitation, the ability of the Company to develop its products, as well as
general market conditions, competition and pricing.  Although the Company
believes that the assumptions underlying the forward-looking statements

                                    -17-
<PAGE>

contained herein are reasonable, any of the assumptions could be inaccurate,
and therefore, there can be no assurance that the forward-looking statements
included in this Form 10-Q will prove to be accurate.  In light of the
significant uncertainties inherent in the forward-looking statements
included herein, the inclusion of such information should not be regarded as
a representation by the Company or any other person that the objectives and
plans of the Company will be achieved.




















































                                    -18-
<PAGE>

                        E-Z-EM, Inc. and Subsidiaries

                         Part II:  Other Information


Item 6.  Exhibits and Reports on Form 8-K
         --------------------------------

(a)  Exhibits
     --------

     No.          Description                                           Page
     ---          -----------                                           ----

    27      Financial data schedule - thirty-nine weeks ended
              February 28, 1998                                          20
    27.1    Financial data schedule - twenty-six weeks ended
              November 30, 1996                                          21
    27.2    Financial data schedule - fifty-two weeks ended
              June 1, 1996                                               22

(b)  Reports on Form 8-K
     -------------------

     No reports on Form 8-K were filed during the quarter ended February 28,
1998.


                                 SIGNATURES

     Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by
the undersigned thereunto duly authorized.




                                          E-Z-EM, Inc.
                                         -----------------------------------
                                          (Registrant)




Date     April 13, 1998                   /s/ Howard S. Stern
     ---------------------               -----------------------------------
                                          Howard S. Stern, Chairman of the
                                          Board, President, Chief Executive
                                          Officer and Director




Date     April 13, 1998                   /s/ Dennis J. Curtin
     ---------------------               -----------------------------------
                                          Dennis J. Curtin, Vice President-
                                          Chief Financial Officer









                                    -19-